Neuromodulation Devices Global Market –Forecast to 2029 is estimated to be worth $9,427.7 million by 2029

IQ4I Research & Consultancy published a new report on “Neuromodulation devices global market – Forecast To 2029” 

This Neuromodulation devices global market report covers four segments namely Product, Application, End-user and Geography. These segments are further segmented as follows:

 Neuromodulation Devices Global Market, Based on Product:

  • Invasive Neuromodulation Devices
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Sacral Nerve Stimulation (SNS)
  • Vagus Nerve Stimulation (VNS)
  • Hypoglossal Nerve Stimulation (HGNS)
  • Others
    • Gastric Electrical Stimulation (GES)
    • Respiratory Electrical Stimulation (RES)/Phrenic Nerve Electrical Stimulation (PNS)
    • Corotid Sinus Stimulation (CSS)
    • Responsive Neurostimulation  (RNS)
  • Non-invasive Neuromodulation Devices
  • Transcutaneous Electrical Nerve Stimulation  (TENS)
  • Neuromuscular Electrical Stimulation (NMES)
  • Others
    • Transcranial Magnetic Stimulation (TMS)
    • Tibial Nerve Stimulation (TNS)
    • Portable Neuromodulation Stimulation (PoNS)
    • Transcranial Electric Stimulation (tES)
    • Transcranial Direct Current Stimulation (tDCS)
    • Transcranial Alternating Current Stimulation (tACS)
    • Peripheral Nerve Stimulation (pNS)
    • Trigeminal Nerve Stimulation (tNS)
    • Percutaneous Electrical Nerve Stimulation (PENS)
    • Transcranial Electro Magnetic Treatment (TEMT)
    • Vestibular nerve stimulation (VeNS)
    • Pharyngeal electrical stimulation (PES)
    • Non – invasive vagus nerve stimulation (n – VNS)
    • Non – invasive spinal cord  nerve stimulation

Neuromodulation Devices Global Market, Based on Application:

  • Pain Management
    • Chronic Pain
    • Failed Back Surgery Syndrome (FBSS)
    • Others
  • Central Nervous System
    • Parkinson’s Disease
    • Dystonia
    • Epilepsy
    • Others (Obsessive Compulsive Disorder, Depression, Stroke, Mood disorders, Anxiety, Multiple Sclerosis, Central Sleep Apnea)
  •     Gastroenterology and Urology
    • Gastroparesis
    • Urinary Incontinence
    • Faecal Incontinence
  •      Obstructive Sleep Apnea (OSA)
  •  Other Applications (Obesity, Heart Failure, Autoimmune Diseases (Rheumatoid Arthritis, Respiratory Related Diseases and Weaning


Neuromodulation Devices Global Market, Based on End-User

  • Hospitals and Ambulatory Surgery Centers
  • Clinics and Physiotherapy Centers
  • Others (Home Care, Academics and Research Institutes)

Neuromodulation Devices Global Market, Based on Geography:

  • North America (U.S. and Rest of NA)
  • Europe (Germany, France, U.K., and Rest of Europe)
  • Asia-Pacific (Japan, China, India, and Rest of APAC)
  • Rest of World (Brazil, Rest of Latin America and Middle East and Others)


Each segment of this report offers market values for its sub-segments and geographies as well. It also provides market dynamics with respect to drivers, restraints, opportunities, and the performance of major key players.

As estimated by IQ4I Research, the Neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029. The factors such as increasing prevalence of chronic pain conditions, central nervous system disorders such as Parkinson disease, Alzheimer disease, Multiple sclerosis, Epilepsy and others (According to U.S. Parkinson’s U.S. foundation, nearly one million people in the U.S. are living with Parkinson's disease (PD) and this number is expected to rise to 1.2 million by 2030. The prevalence of Parkinson’s in the U.K. is a total of about 127,000 people living with the disease, The prevalence of epilepsy is estimated to be 5.0 million people in U.S. in 2022), low approval rate of CNS drugs and favorable reimbursement scenario in major markets are driving the neuromodulation market. The emergence of neuromodulation as add-on therapy, technological innovations in neuromodulation, expansion in emerging markets and the rise in the number of clinical studies performed provides immense opportunities to the neuromodulation market. However, side effects and risks associated with the use, lack of trained professionals, availability of alternative treatments and stringent regulatory guidelines are expected to hamper the market growth.

The report covers business intelligence information of the Neuromodulation devices global market segments based on product, application, end - users and geography. Revenue forecast and strategic analysis with respect to industry trends and contribution to the overall Neuromodulation device global market. Analysis of average selling price (ASP), overall market share, market share analysis of major players, number of units of SCS, DBS, SNS, VNS and HGNS based on region, reimbursement scenario, funding scenario, clinical trials, supply chain of neuromodulation devices and product matrix. Identification of major market trends, factors driving, restraining, threatening and providing opportunities for the neuromodulation devices market growth. Major players’ company profiles in the Neuromodulation devices Global market and analysis of their business strategies and market shares.

Major players in the Neuromodulation devices global market are Medtronic Plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), LivaNova Plc (U.K.), Nevro Corporation (U.S.), Inspire Medical Technologies (U.S.), Bioventus (Bioness Inc) (U.S.), Neuropace Inc. (U.S.), Laborie Medical System Inc. (U.S.), Axonics Inc. (U.S.) and others